在铂耐药或难治性上皮性卵巢癌患者中比较吉西他滨联合阿达沃塞替布或安慰剂的随机双盲安慰剂对照II期试验中患者使用PRO-CTCAE自我报告耐受性
该随机双盲安慰剂对照II期试验在铂耐药或难治性高级别浆液性卵巢癌患者中评估吉西他滨联合WEE1抑制剂阿达沃塞替布或安慰剂,PRO-CTCAE探索性分析显示阿达沃塞替布组吞咽困难和疲劳严重程度自报发生率更高。
要点
- 阿达沃塞替布组吞咽困难阳性PRO-CTCAE评分比例高于安慰剂组(35.7% vs 5.3%,p=0.02)。
- 阿达沃塞替布组高评分(≥3)腹泻发生率高于安慰剂组(25% vs 0%,p=0.03)。
- 阿达沃塞替布组吞咽困难和疲劳严重程度随时间加重的比例均高于安慰剂组。
核心结论
- 患者自报耐受性的纵向评估显示,接受吉西他滨/阿达沃塞替布的患者吞咽困难和疲劳严重程度高于吉西他滨/安慰剂组。
- PRO-CTCAE从患者视角提供了药物耐受性的补充和客观评估。
研究设计与样本
- 随机双盲安慰剂对照II期试验的探索性分析,在铂耐药或难治性高级别浆液性卵巢癌患者中比较吉西他滨联合阿达沃塞替布或安慰剂。
- PRO-CTCAE在基线、每周期第1天和第15天及治疗结束时完成,在两个中心进行,旨在描述治疗前三个月的症状性不良事件。
- 61例患者被邀请参与PRO-CTCAE调查,55例可评估;高级别浆液性卵巢癌患者中28例接受吉西他滨/阿达沃塞替布(A组),19例接受吉西他滨/安慰剂(B组)。
主要发现
- 吞咽困难阳性(≥1)PRO-CTCAE评分比例A组35.7% vs B组5.3%(p=0.02)。
- 高评分(≥3)症状性不良事件中,腹泻A组25% vs B组0%(p=0.03)。
- 随时间加重的症状性不良事件比例:吞咽困难A组35.7% vs B组5.3%(p=0.03);疲劳严重程度A组71.43% vs B组42.1%(p=0.04)。
- 调查完成率高。
关键数值与推荐
- 吞咽困难阳性(≥1)PRO-CTCAE评分比例A组35.7% vs B组5.3%(p=0.02)。
- 高评分(≥3)腹泻比例A组25% vs B组0%(p=0.03)。
- 吞咽困难随时间加重比例A组35.7% vs B组5.3%(p=0.03)。
- 疲劳严重程度随时间加重比例A组71.43% vs B组42.1%(p=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A double-blind, randomized, placebo-controlled, phase 2 trial assessed gemcitabine in combination with the wee1 inhibitor adavosertib or placebo in platinum resistant or refractory high grade serous ovarian cancer (HGSOC), demonstrating improved progression free and overall survival favouring the adavosertib/gemcitabine arm. An exploratory objective of the study included the PRO-CTCAE assessment, to capture self-reporting of frequency, severity and/or interference of symptomatic adverse events (syAEs). METHODS: PRO-CTCAE items at baseline, days 1 and 15 of each cycle and off treatment, were completed in two centres, with the objective of characterizing syAEs in the first three months of therapy. The maximum post-baseline score proportion for each syAE was tabulated per patient. The 12-week area under the curve (AUC12w) as a measure of syAE over-time and incremental AUC12w (iAUC12w) for adjustment to baseline syAEs. RESULTS: Sixty-one patients were approached for PRO-CTCAE surveys and 55 were evaluable. Among patients with HGSOC, 28 received gemcitabine/adavosertib (arm A) and 19 gemcitabine/placebo (arm B). Survey completion rates were high. The proportion of participants with positive (≥1) PRO-CTCAE scores was higher for difficulty swallowing with gemcitabine/adavosertib (arm A 35.7% vs arm B 5.3%, p = 0.02). The high score (≥3) syAEs showed more frequent diarrhea with gemcitabine/adavosertib (arm A 25% vs arm B 0%, p = 0.03). The proportions of worsening syAEs over time were higher in patients receiving gemcitabine/adavosertib for difficulty swallowing (arm A 35.7% vs arm B 5.3%; p = 0.03) and fatigue severity (arm A 71.43% vs arm B 42.1%; p = 0.04). CONCLUSIONS: The longitudinal assessment of patient self-reported tolerability showed greater difficulty swallowing and fatigue severity in patients receiving gemcitabine/adavosertib, compared to gemcitabine/placebo. PRO-CTCAE provides complementary and objective assessment of drug tolerability from a patient's perspective.
引用
- Madariaga A, Mitchell SA, Pittman T, et al. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma. Gynecol Oncol. 2022. PMID: 36055813. doi:10.1016/j.ygyno.2022.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。